Water volumes for 5, 10 and 20 mg SLU-PP-332 vials, the resulting mg/mL, U-100 units for the circulating figures, and the solubility data behind them.
This page does one thing: the arithmetic for SLU-PP-332 vials. Water volume per vial size, the concentration that results, and what the figures circulating for this compound come to in U-100 syringe units. Every figure carries its source and the date it was read. Nothing here is a recommendation.
SLU-PP-332 is not a peptide. It is a small synthetic molecule, C18H14N2O2, molecular weight 290.3 (PubChem CID 5338394, read 2026-09-18), that activates the three estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma. It is sold through the same channel as research peptides, in lyophilized vials and in capsules and tablets. The vial presentation is what this page works; the SLU-PP-332 calculator works the same arithmetic for any vial and water volume. Medibact's SLU-PP-332 guide covers what the compound is and what the research holds.
What the sources hold
There is no label. A DailyMed search on 2026-09-18 returned zero records, so no regulator has reviewed a dose, a route or a storage condition for this molecule.
There is no registration. ClinicalTrials.gov held no study naming SLU-PP-332 on 2026-09-18.
There are ten papers. A PubMed title-and-abstract search on 2026-09-18 returned 10 records: the 2023 ACS Chemical Biology paper that introduced the compound as an exercise mimetic in mice (PMID 36988910), a 2024 Journal of Pharmacology and Experimental Therapeutics paper on obese and ob/ob mice (PMID 37739806), a 2024 Circulation paper on heart failure in mice (PMID 37961903), a 2023 American Journal of Pathology paper on the ageing kidney in 21-month-old mice (PMID 37717940), a 2025 Frontiers in Physiology pilot study that treated muscle cells cultured from the biopsies of 20 women with the compound in the dish (PMID 40692696), two 2026 analytical papers on detecting its metabolites for doping control, a 2026 structure-activity chemistry paper, a 2026 systematic review in Revista Medica de Chile whose conclusion is that clinical trials are needed (PMID 42024694), and the January 2026 paper from the compound's own laboratory stating that SLU-PP-332 "improves aerobic performance in mice but lacks oral bioavailability" (PMID 41421047). The in vivo dose the supplier cites from that work is 50 mg/kg twice per day by injection (Cayman Chemical, item 41719, read 2026-09-18). Peptifact's SLU-PP-332 dosage page reports the vehicle from the Circulation methods as 5 mg/mL in 12% DMSO and 15% Cremophor in phosphate-buffered saline; the full texts sat behind a verification page when this site requested them on 2026-09-18, so that detail is cited to that reading rather than quoted here.
Water per vial and the resulting concentration
The vial sizes the site's calculator carries are 5 mg, 10 mg and 20 mg, matching what the research market lists. Concentration is the vial amount divided by the water volume.
| Vial |
1 mL of water |
2 mL of water |
3 mL of water |
| 5 mg |
5 mg/mL |
2.5 mg/mL |
1.67 mg/mL |
| 10 mg |
10 mg/mL |
5 mg/mL |
3.33 mg/mL |
| 20 mg |
20 mg/mL |
10 mg/mL |
6.67 mg/mL |
More water means a lower concentration and a larger, easier-to-read syringe draw for the same quantity; less water means the opposite. Neither changes the quantity in the vial.
A U-100 insulin syringe reads 100 units per millilitre, so units = quantity in mg divided by mg/mL, times 100. The quantities below are the ones that appear on vendor and protocol pages for the injectable presentation (read 2026-09-18); none of them comes from a human study, because there is none.
| Quantity |
2.5 mg/mL |
5 mg/mL |
10 mg/mL |
20 mg/mL |
| 250 mcg |
10 units |
5 units |
2.5 units |
1.25 units |
| 500 mcg |
20 units |
10 units |
5 units |
2.5 units |
| 1 mg |
40 units |
20 units |
10 units |
5 units |
| 5 mg |
200 units (two syringes) |
100 units (full syringe) |
50 units |
25 units |
Two readings from the table. At 20 mg/mL the sub-milligram quantities land on quarter-units, below the resolution of any insulin syringe scale; more water fixes that. At 2.5 mg/mL a 5 mg quantity exceeds one syringe. The insulin syringe units page covers the scales and the barrel sizes.
Solubility: why this vial behaves differently
Cayman Chemical's product page states SLU-PP-332 is "sparingly soluble" in DMSO at 1 to 10 mg/mL and "slightly soluble" in ethanol at 0.1 to 1 mg/mL, and gives no aqueous solubility (read 2026-09-18). Water-based reconstitution of a plain lyophilized vial may therefore leave undissolved material, and the concentrations in the tables above describe the solution only if the solid actually dissolves. Some suppliers add a small amount of co-solvent to the vial for this reason, and a vial labelled that way is a different preparation from a plain one. The label of the vial in hand is the authority on what it contains; the tables use the labelled milligram figure, which is all any calculator can do.
The mixing steps, as labels describe them
No SLU-PP-332 label exists, so the steps come from the labelled peptide products prepared the same way. The EGRIFTA WR label (tesamorelin, revised 3/2025) directs that the diluent be added to the vial and the vial moved in a circle to mix, and states: do not shake. The EGRIFTA SV label (revised 2/2024) states that the vial is mixed by rolling it gently between the hands for 30 seconds, and again: do not shake (DailyMed, read 2026-09-18). The general procedure for research vials, step by step, is on Medibact's page on how to reconstitute peptides; this page does not repeat it.
Storage after mixing
No product label states a storage condition for reconstituted SLU-PP-332, and the supplier's only figure is minus 20 degrees Celsius for the dry powder (Cayman Chemical, read 2026-09-18); Medibact's article on how to store peptides covers storage of reconstituted vials.
The circulating figures span two orders of magnitude and disagree on the route. Protocol and vendor pages read on 2026-09-18 state oral figures of 250 mcg to about 1.5 mg a day, 5 to 25 mg a day, and a 50 mg tablet taken once daily, and injectable-vial pages work a 10 mg vial in 2 mL to 5 mg/mL with 500 mcg per 10 units. Against those figures stand a mouse dose given by injection, a developer's statement that the molecule is not orally available, and no human pharmacokinetics at all: no half-life, no bioavailability, no dose-response in any person. What every figure omits is therefore route, frequency, duration and population, because none has been studied in humans. The SLU-PP-332 dosage page sets each circulating figure against its source, the site's dosage chart carries the compound's row, and the dosage hub indexes the per-compound pages.
Related pages
The SLU-PP-332 calculator returns concentration and units for any vial and water volume. The reconstitution hub indexes every compound page and the chart. The weight-loss stack page covers the metabolic compounds this molecule is sold beside. For two vials drawn together, the blend calculator does the per-component arithmetic.
This page does not recommend a dose, a route, a water volume or a schedule. It reports what a supplier, a registry and ten papers state, and it does the arithmetic on the vial sizes sold.
Sources and dates
Opened 2026-09-18: PubChem CID 5338394 (formula and molecular weight); Cayman Chemical product page for item 41719 (formal name, CAS 303760-60-3, solubility, storage, the 50 mg/kg twice-daily mouse dose); the DailyMed SPL search API for SLU-PP-332 (zero records); the ClinicalTrials.gov v2 API for SLU-PP-332 (zero registrations); PubMed through the NCBI E-utilities for "SLU-PP-332"[tiab] (10 records, summaries retrieved) and the abstracts of PMID 36988910, 37739806, 37961903, 41421047 and 42024694; the EGRIFTA WR and EGRIFTA SV labels on DailyMed (setids 839334d3-8c1d-4c26-9036-2ab524a6ea75 and 3d783378-b02d-4f19-99dd-0fc91a042224) for the mixing wording; protocol and vendor pages carrying oral and injectable figures, read the same day; Peptifact's SLU-PP-332 dosage page for the vehicle detail. Corrections go to the contact page.
